Lilly, AstraZeneca Alzheimer's Trial Advances

11.04.2016 - Eli Lilly and AstraZeneca are moving into Phase 3 of their Amaranth study of AZD3293, an oral beta secretase cleaving enzyme (BACE) inhibitor that could be a potential treatment...